GlassScriptPhysician profile
Igor J Nastaskin
NPI 1619014776
$7,511.14
in general payments reported to CMS, 2019-2025
32 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $234 · 2021: $1,066 · 2022: $1,556 · 2023: $1,349 · 2024: $1,357 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,251.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,376.70 | 2019-2025 | |
| Janssen Biotech, INC. | $757.01 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $272.48 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.09 | 2019-2024 | Xifaxan |
| Pfizer INC. | $216.71 | 2019-2025 | |
| Madrigal Pharmaceuticals | $185.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Ethicon US, LLC | $172.72 | 2023 | Neuwave |
| Phathom Pharmaceuticals, INC. | $172.16 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $129.46 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $125.61 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $91.56 | 2019-2021 | |
| Gilead Sciences, INC. | $79.23 | 2021-2025 | |
| Braintree Laboratories, INC. | $74.13 | 2021-2023 | Sutab |
| Celgene Corporation | $70.44 | 2021-2022 | |
| Shionogi INC | $64.38 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $48.32 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.25 | 2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $46.65 | 2020-2022 | |
| Allergan, INC. | $41.33 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $37.85 | 2024-2025 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $33.92 | 2023 | Andexxa |
| Qol Medical, LLC | $33.54 | 2024 | Sucraid |
| Medtronic, INC. | $31.84 | 2022-2023 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $27.24 | 2021-2022 | |
| Redhill Biopharma INC. | $25.81 | 2024 | Talicia |
| Boston Scientific Corporation | $25.01 | 2022 | |
| Meridian Bioscience INC. | $23.96 | 2020 | |
| Enterra Medical, INC. | $21.49 | 2024 | |
| Genzyme Corporation | $20.92 | 2023 | |
| Novo Nordisk INC | $19.42 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $13.74 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Nastaskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.